Zoetis Inc. (NYSE:ZTS) Shares Purchased by EP Wealth Advisors LLC

EP Wealth Advisors LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 1.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 247,100 shares of the company's stock after acquiring an additional 4,498 shares during the period. EP Wealth Advisors LLC owned about 0.05% of Zoetis worth $40,260,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ZTS. Atlantic Edge Private Wealth Management LLC boosted its stake in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. lifted its holdings in Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after buying an additional 166 shares in the last quarter. Navigoe LLC bought a new position in Zoetis in the 4th quarter worth about $30,000. Murphy & Mullick Capital Management Corp bought a new position in Zoetis in the 4th quarter worth about $44,000. Finally, Asset Planning Inc purchased a new position in shares of Zoetis during the fourth quarter worth approximately $58,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on ZTS. Stifel Nicolaus dropped their price objective on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Finally, Piper Sandler boosted their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Zoetis presently has an average rating of "Buy" and an average target price of $212.13.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares of the company's stock, valued at $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,862 shares of company stock worth $312,254. Company insiders own 0.18% of the company's stock.

Zoetis Stock Down 1.1 %

Shares of Zoetis stock traded down $1.73 during trading on Friday, reaching $159.96. The company's stock had a trading volume of 4,243,109 shares, compared to its average volume of 2,491,045. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a 50-day simple moving average of $157.27 and a two-hundred day simple moving average of $166.22. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a market cap of $71.37 billion, a price-to-earnings ratio of 29.24, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company's revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.38 earnings per share. As a group, equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.